Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796127 | 1.00 | GAA (0.38) | GAAUSP2L3MBTL1ALDH1A1CYP2D6 | |
| SCHEMBL24796115 | 1.00 | GAA (0.38) | GAAUSP2L3MBTL1ALDH1A1CYP2D6 | |
| SCHEMBL24796132 | 1.00 | GAA (0.38) | GAAUSP2L3MBTL1ALDH1A1CYP2D6 | |
| SCHEMBL26746701 | 0.88 | KMT2A (0.33) | USP2ALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL24796301 | 0.88 | HSD17B10 (0.35) | USP2ALDH1A1TP53POLBMAPT | |
| SCHEMBL21389158 | 0.87 | USP2 (0.39) | GAAUSP2L3MBTL1ALDH1A1FABP4 | |
| SCHEMBL24795885 | 0.87 | USP2 (0.39) | GAAUSP2L3MBTL1ALDH1A1FABP4 | |
| SCHEMBL21389252 | 0.87 | GAA (0.33) | GAAUSP2L3MBTL1ALDH1A1FABP4 | |
| SCHEMBL21389177 | 0.85 | GAA (0.36) | GAAUSP2L3MBTL1ALDH1A1CYP2D6 | |
| SCHEMBL21389394 | 0.84 | GAA (0.38) | GAAUSP2L3MBTL1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3768294-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | GAA 1526/4885USP2 2595/4885L3MBTL1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.